ISRCTN39575233已完成不适用
A randomized, placebo-controlled, partially blinded (drug versus placebo) trial of early corticosteroid therapy in Vietnamese children and young adults with suspected dengue infection
niversity of Oxford (UK)0 个研究点目标入组 225 人开始时间: 2008年10月21日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 225
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Aged between 6 and 20 years, either sex
- •2. Weight at least 20 kg
- •3. Clinical suspicion of dengue, with a positive rapid test for dengue non-structural protein 1
- •4. Fever for less than or equal to 72 hours
- •5. Informed consent
排除标准
- •1. Signs or symptoms suggestive of any other acute infectious disease
- •2. Any evidence of significant complications of dengue, e.g., mucosal bleeding, jaundice, neurological compromise, shock, inability to tolerate oral medication
- •3. Any prior history of serious physical illness, or any chronic condition requiring regular follow up
- •4. Any history of psychiatric disorder or behaviour disturbance
- •5. Current or recent (within 3 months) use of any medication other than drugs for symptomatic relief (analgesics, decongestants, etc.)
- •6. Any history of an adverse drug reaction to any medication
- •7. Pregnancy (enrolment within one month of last menstrual period [LMP] in post-pubertal females)
研究者
相似试验
已完成
2 期
Phase II Study of H4:IC31 and BCG revaccination in Healthy Adolescents (040-404)TuberculosisPACTR201512001069358Aeras990
进行中(未招募)
1 期
Study of efficacy and safety of VAY736 in patients with relapsing-remitting multiple sclerosisEUCTR2013-002324-16-PLovartis Pharma Services AG96
进行中(未招募)
1 期
Study of efficacy and safety of VAY736 in patients with relapsing-remitting multiple sclerosisrelapsing-remitting multiple sclerosisMedDRA version: 17.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2013-002324-16-CZovartis Pharma Services AG96
进行中(未招募)
1 期
A study to asses the effects of cannabidiol (CBD) on liver fat levels with people who have fatty liver diseaseEUCTR2009-017080-41-GBGW Pharma Ltd.25
已完成
不适用
A Blinded, Placebo-Controlled, Randomized, Single Ascending Dose Study in Healthy Male Subjects to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-37822681psychosis10039628NL-OMON30850Johnson & Johnson Pharmaceutical24
